San Francisco, California, United States | Fund Name | Location |
| ALMEX Japan | Japan, Tokyo |
| Arroba Capital | Barcelona, Catalonia, Spain |
| Biopartners Capital | - |
| Boston Global Ventures | Cambridge, Massachusetts, United States |
| BrainPOP | New York, New York, United States |
| Caissa Touristic | Germany, Hamburg |
| Champion Motors | Bene Beraq, Israel, Tel Aviv |
| China Oceanwide | Beijing, Beijing, China |
| Clarium Capital | New York, New York, United States |
| Council of Smaller Enterprises (COSE) | - |
| CPA.com | New York, New York, United States |
| DB Investment Partners | New York, New York, United States |
| Difference Capital | Canada, Ontario, Toronto |
| Dongzheng Rongtong Investment | Beijing, Beijing, China |
| G2 Capital | - |
| Grameen Impact India (GIII) | India, Pennsylvania, United States |
| Laodong Fabaowang | China, Guangdong, Guangzhou |
| Precedo Capital Group | Arizona, Paradise Valley, United States |
| Senju Pharmaceutical | - |
| Startup42 | France, Ile-de-France, Paris |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Fizimed | $708K | 23 Mar 2018 | Grand Est |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Fizimed | $708K | 23 Mar 2018 | Grand Est |
